Digital Mammography Firms Decry Clinical Trial Provisions In Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome